Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

Added 203 days ago (10.12.2021)
Authors: Charlotte S Wilhelm-Benartzi; Sarah E Miller; Sylvaine Bruggraber; Diane Picton; Mark Wilson; Katrina Gatley; Anita Chhabra; M Loredana Marcovecchio; A Emile J Hendriks; Hilde Morobé; Piotr Jaroslaw Chmura; Simon Bond; Bärbel Aschemeier-Fuchs; Mikael Knip; Timothy Tree; Lut Overbergh; Jaivier Pall; Olivier Arnaud; Michael J Haller; Almut Nitsche; Anke M Schulte; Chantal Mathieu; Adrian Mander; David Dunger
Read article